Aima Biotechnology

Aima Biotechnology is a clinical-stage synthetic biology company based in Shanghai, China, dedicated to developing engineered live biotherapeutic products (LBPs). The company utilizes a proprietary platform to design and construct living medicines—genetically engineered bacteria that colonize the human gut to treat metabolic and inflammatory diseases. Its lead candidate, AIM-001, is an engineered probiotic designed to degrade uric acid in the intestine for the treatment of hyperuricemia and gout, and is currently undergoing Phase 1 clinical trials. Aima's pipeline also includes programs for rare metabolic disorders such as phenylketonuria and various oncology indications. Backed by leading investors like Matrix Partners China and IDG Capital, the company aims to establish a new paradigm in medicine through the precision engineering of the human microbiome.